USP7 and prostate carcinoma: In comparison to the clinically relevant MDM2 inhibitors, compound 4 has equal or superior anticancer activity in acute lymphoblastic leukemia cell line RS4;11 and prostate cancer cell line LNCaP, which are hypersensitive to USP7 inhibition (Gavory et al., 2018).